Morquio syndrome (mucopolysaccharidosis IV: MPS IV) is an autosomal recessive disease classified in the group of mucopolysaccharide storage diseases. Two forms are recognized, type A and type B. MPS IVA is characterized by the absence of the enzyme N-acetylgalactosamine 6-sulfate sulfatase (GALNS). MPS IVB results from deficiency of the enzyme β-galactosidase. Both types excrete keratan sulfate (KS) in urine. In 1929, Morquio, a pediatrician in Uruguay, described cases of Morquio syndrome. In 1952, Brante isolated the stored mucopolysaccharides in Morquio patients. In 1976, the enzyme deficiency in MPS IVA (GALNS deficiency) was identified (Singh et al. 1976). Shortly thereafter, the enzyme deficiency in MPS IVB was described (β-galactosidase deficiency). Historically, MPS IVA was considered to have more severe manifestations than MPS IVB. However, with the ability to differentiate between types A and B by enzyme analysis, variability in clinical expression in both groups becomes apparent. Recently, three different MPS IVA mice models have been established (Tomatsu et al., 2003b; unpublished data). Clinical manifestations in the affected mice are milder than those in human patients. Only palliative measures are currently available for treatment of patients with MPS IV. Potential strategies, currently at different levels of development, include enzyme replacement, gene therapy, and allogenic bone marrow transplantation in which engrafted cells provide the normal enzyme. Those treatments are expected to enable dramatic improvements in visceral organs but little or no improvements in bone because the enzymes are not delivered to the bone effectively. In this context, the challenge still is to maximize the clinical efficacy to the bones, especially to systematic bone disease, MPS IV. In this chapter, we review the clinical manifestations, incidence, diagnosis, and treatments for MPS IV, mainly focusing on IVA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bond, C.S., Clements, P.R., Ashby, S.J., Collyer, C.A., Harrop, S.J., Hopwood, J.J., and Guss, J.M., 1997, Structure of a human lysosomal sulfatase, Structure 5:277-289.
Brante, G., 1952, Gargoylism, a mucopolysaccharidosis, Scand. J. Clin. Lab. Invest. 4:43.
Bunge, S., Kleijer, W.J., Tylki-Szymanska, A., Steglich, C., Beck, M., Tomatsu, S., Fukuda, S., Poorthuis, B.J., Czartoryska, B., Orii, T., and Gal, A., 1997, Identification of 31 novel mutations in the N-acetylgalactosamine-6-sulfatase gene reveals excessive allelic heterogeneity among patients with Morquio A syndrome, Hum. Mutat. 10:223-232.
Cosma, M.P., Pepe, S., Annunziata, I., Newbold, R.F., Grompe, M., Parenti, G., and Ballabio, A., 2003, The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases, Cell. 113:445-456.
Dierks, T., Schmidt, B., Borissenko, L.V., Peng, J., Preusser, A., Mariappan, M., and von Figura, K., 2003, Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C (alpha)-formylglycine generating enzyme, Cell. 113:435-444.
Dullenkopf, A., Holzmann, D., Feurer, R., Gerber, A., and Weiss, M., 2002, Tracheal intubation in children with Morquio syndrome using the angulated video-intubation laryngoscope, Can J Anaesth. 49:198-202.
Fang-Kircher, S.G., Herkner, K., Windhager, R., and Lubec, G., 1997, The effects of acid glycosaminoglycans of neonatal calvarian cultures- A role of keratan sulfate in Morquio syndrome?, Life Sci. 61:771-775.
Fujimoto, A., and Horwitz, A.L., 1983, Biochemical defect of non-keratan-sulfate-excreting Morquio syndrome, Am. J. Med. Genet. 15:265-273.
Fukuda, S., Tomatsu, S., Masue, M., Sukegawa, K., Iwata, H., Ogawa, T., Nakashima, Y., Hori, T., Yamagishi, A., Hanyu, Y., Morooka, K., Kiman, T., Hashimoto, T., and Orii, T., 1992, Mucopolysaccharidosis type IVA: N-Acetylgalactosamine-6-sulfate sulfatase exonic point mutations in classical Morquio and mild cases, J. Clin. Invest. 90:1049-1053.
Hori, T., Tomatsu, S., Nakashima, Y., Uchiyama, A., Fukuda, S., Sukegawa, K., Shimozawa, N., Suzuki, Y., Kondo, N., and Horiuchi, T., Ogura, S., and Orii, T., 1995, Mucopolyaccharidosis type IVA: Common double deletion at the N-acetylgalactosamine-6-sulfate sulfatase gene, Genomics. 26:535-542.
Kakkis, E.D., Muenzer, J., Tiller, G.E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., Hoft, R., and Neufeld, E.F., 2001, Enzymereplacement therapy in mucopolysaccharidosis I, N Engl J Med. 344:182-188.
Kato, Z., Fukuda, S., Tomatsu, S., Vega, H., Yasunaga, T., Yamagishi, A., Yamada, N., Valencia, A., Barrera, L.A., Sukegawa, K., Orii, T., and Kondo, N., 1997, A novel common missense mutation G301C in the N-acetylgalactosamine-6-sulfate sulfatase gene in mucopolysaccharidosis IVA, Hum. Genet. 101:97-101.
Kornfeld, S., and Mellman, I., 1989, The biogenesis of lysosomes, Annu Rev Cell Biol. 5:483-525.
Lund-Hansen, T., Hoyer, P.E., Andersen, H., 1984, A quantitative cytochemical assay of beta-galactosidase in single cultured human skin fibroblasts, Histochemistry 81:321-330.
Masue, M., Sukegawa, K., Orii, T. and Hashimoto, T., 1991, N-acetylgalactosamine-6-sulfate sulfatase in human placenta: purification and characteristics, J Biochem (Tokyo). 110:965-970.
Montaño, A.M., Kaitila, I., Sukegawa, K., Tomatsu, S., Kato, Z., Nakamura, H., Fukuda, S., Orii, T., and Kondo, N., 2003, Mucopolysaccharidosis IVA: characterization of a common mutation found in Finnish patients with attenuated phenotype, Hum. Genet. 113:162-169.
Morquio, L., 1929, Sur une forme de dystrophie osseuse familiale, Bull. Soc. Pediat. Paris 27:145.
Nakashima, Y., Tomatsu, S., Hori, T., Fukuda, S., Sukegawa, K., Kondo, N., Suzuki, Y., Shimozawa, Y., and Orii, T., 1994, Mucopolysaccharidosis IVA: molecular cloning of the human N-acetylgalactosamine 6-sulfatase (GALNS) gene and analysis of the 5’-flanking region, Genomics. 20:99-104.
Ogawa, T., Tomatsu, S., Fukuda, S., Yamagishi, A., Rezvi, G.M., Sukegawa, K., Kondo, N., Suzuki, Y., Shimozawa, N., and Orii, T., 1995, Mucopolysaccharidosis IVA: screening and identification of mutations of the N-acetyl galactosamine-6-sulfate sulfatase gene, Hum. Mol. Genet. 4:341-349.
Oshima, A., Tsuji, A., Nagao, Y., Sakuraba, H., Suzuki, Y., 1988, Cloning, sequencing, and expression of cDNA for human beta-galactosidase, Biochem. Biophys. Res. Commun. 1988, 157:238-244.
Oshima, A., Yoshida, K., Shimmoto, M., Fukuhara, Y., Sakuraba, H., and Suzuki, Y., 1991, Human beta-galactosidase gene mutations in morquio B disease, Am J Hum Genet. 49:1091-1093.
Schmidt, B., Selmer, T., Ingendoh, A., and von Figura, K., 1995, A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency, Cell 82:271-278.
Singh, J., DiFerrante, N.M., Niebes, P., and Travella, D., 1976, N-acetylgalactosamine-6-sulfate sulfatase in man: absence of the enzyme in Morquio disease, J. Clin. Invest. 57:1036.
Sukegawa, K., Nakamura, H., Kato, Z., Tomatsu, S., Montaño, A.M., Fukao, T., Toietta, G., Tortora, P., Orii, T., and Kondo, N., 2000, Biochemical and structural analysis of missense mutations in N-acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes, Hum. Mol. Genet. 22:1283-1290.
Terzioglu, M., Tokatli, A., Coskun, T., and Emre, S., 2002, Molecular analysis of Turkish mucopolysaccharidosis IVA (Morquio A) patients: Identification of novel mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene, Hum. Mutat. 20:477-478.
Toietta, G., Severini, G.M., Traversari, C., Tomatsu, S., Sukegawa, K., Fukuda, S., Kondo, N., Tortora, P., and Bordignon, C., 2001, Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro, Hum Gene Ther. 12:2007-2016.
Tomatsu, S., Fukuda, S., Cooper, A., Wraith, J.E., Ferreira, P., Di Natale, P., Tortora, P., Fujimoto, A., Kato, Z., Yamada, N., Isogai, K., Yamagishi, A., Sukegawa, K., Suzuki, Y., Shimozawa, N., Kondo, N., Sly, W.S., and Orii, T., 1997, Fourteen novel mucopolysaccharidosis IVA producing mutations in GALNS gene, Hum. Mutat. 10:368-375.
Tomatsu, S., Fukuda, S., Cooper, A., Wraith, J.E., Rezvi, G.M., Yamagishi, A., Yamada, N., Kato, Z., Isogai, K., Sukegawa, K., Kondo, N., Suzuki, Y., Shimozawa, N., and Orii, T., 1995a, Mucopolysaccharidosis IVA: Identification of a common missense mutation I113F in the N-acetylgalactosamine-6-sulfate sulfatase gene, Am. J. Hum. Genet. 57:556-563.
Tomatsu, S., Fukuda, S., Cooper, A., Wraith, J.E., Rezvi, G.M., Yamagishi, A., Yamada, N., Kato, Z., Isogai, K., and Sukegawa, K., Kondo, N., Suzuki, Y., Shimozawa, N., and Orii, T., 1995b, Mucopolysaccharidosis type IVA: Identification of six novel mutations among non-Japanese patients, Hum. Mol. Genet. 4:741-743.
Tomatsu, S., Fukuda, S., Masue, M., Sukegawa, K., Fukao, T., Yamagishi, A., Hori, T., Iwata, H., Ogawa, T., Nakashima, Y., Hanyu, Y., Hashimoto, T., Titani, K., Oyama, R., Suzuki, M., Yagi, K., Hayashi, Y., and Orii, T., 1991, Morquio disease: Isolation, characterization and expression of full-length cDNA for human N-acetylgalactos-amine-6-sulfate sulfatase, Biochem. Biophys. Res. Commun. 181:677-683.
Tomatsu, S., Gutierrez, M.A., Nishioka, T., Pena, O., 2004b, Enzyme replacement therapy for mucopolysaccharidosis IVA: Development of bone targeting system, The American Society of Human Genetics, 54th Annual Meeting, Toronto, Ontario,Canada October 26-30: p. 71.
Tomatsu, S., Okamura, K., Taketani, T., Orii, K.O., Nishioka, T., Gutierrez, M.A., Velez-Castrillon, S., Fachel, A.A., Grubb, J.H., Cooper, A., Thornley, M., Wraith, E., Barrera, L.A., Giugliani, R., Schwartz, I.V., Frenking, G.S., Beck, M., Kircher, S.G., Paschke, E., Yamaguchi, S., Ullrich, K., Isogai, K., Suzuki, Y., Orii, T., Kondo, N., Creer, M., and Noguchi, A., 2004a, Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA, Pediatr Res. 5:592-597.
Tomatsu, S., Orii, K.O., Vogler, C., Grubb, J.H., Snella, E.M., Gutierrez, M., Dieter, T., Holden, C.C., Sukegawa, K., Orii, T., Kondo, N., and Sly, W.S., 2003a, Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase, Hum Mol Genet. 12:961-973.
Tomatsu, S., Orii, K.O., Vogler, C., Nakayama, J., Levy, B., Grubb, J.H., Gutierrez, M.A., Shim, S., Yamaguchi, S., Nishioka, T., Montaño, A.M., Noguchi, A., Orii, T., Kondo, N., and Sly, W.S., 2003b, Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease, Hum Mol Genet. 12:3349-3358.
van Diggelen, O.P., Zhao, H., Kleijer, W.J., Janse, H.C., Poorthuis, B.J., vanPelt, J., Kamerling, J.P., and Galjaard, H., 1990, A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A), Clin. Chim. Acta 187:131-139.
Whitley, C.B., Spielmann, R.C., Herro, G., and Teragawa, S.S., 2002, Urinary glycos-aminoglycan excretion quantified by an automated semimicro method in specimens conveniently transported from around the globe, Mol Genet Metab. 75:56-64.
Yamada, N., Fukuda, S., Tomatsu, S., Muller, V., Hopwood, J.J., Nelson, J., Kato, Z., Yamagishi, A., Sukegawa, K., Kondo N., and Orii, T., 1998, Molecular hetero-geneity in mucopolysaccharidosis IVA in Australia and Northern Ireland: Nine novel mutations including T312S, a common allele that confers a mild phenotype, Hum. Mutat. 11:202-208.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Tomatsu, S., Montaño, A.M., Nishioka, T., Orii, T. (2007). Mucopolysaccharidosis IV (Morquio Syndrome). In: Lysosomal Storage Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-70909-3_27
Download citation
DOI: https://doi.org/10.1007/978-0-387-70909-3_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-70908-6
Online ISBN: 978-0-387-70909-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)